InsidersTradesSigma
Follow the ZENAS BIOPHARMA INC share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €2bn. The latest transaction was disclosed on 19 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Zebra Aggregator, LP. The full history is accessible without an account.
Analysts rate ZENAS BIOPHARMA INC Strong Buy (bullish), based on 8 analysts. Average price target: US$47.00.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
ZENAS BIOPHARMA INC is a biopharmaceutical company focused on developing innovative treatments for autoimmune diseases and cancers. It is listed on the NASDAQ under the symbol ZENA.